Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient
Sarolta Bojtine Kovacs,
Jingting Luan,
Sandra Maria Dold,
Andreas Weis,
Milena Pantic,
Justus Duyster,
Ralph Wäsch,
Monika Engelhardt
Affiliations
Sarolta Bojtine Kovacs
Departments of Medicine 1, Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg
Jingting Luan
Departments of Medicine 1, Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg
Sandra Maria Dold
Departments of Medicine 1, Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg;Faculty of Biology, University of Freiburg
Andreas Weis
Departments of Medicine 1, Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg;Comprehensive Cancer Center Freiburg (CCCF), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
Milena Pantic
Departments of Medicine 1, Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg
Justus Duyster
Departments of Medicine 1, Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg;Comprehensive Cancer Center Freiburg (CCCF), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
Ralph Wäsch
Departments of Medicine 1, Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg;Comprehensive Cancer Center Freiburg (CCCF), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
Monika Engelhardt
Departments of Medicine 1, Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg;Comprehensive Cancer Center Freiburg (CCCF), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
